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An immunohistochemical study was performed using tissue microarrays and specific antibodies against matrix metalloproteinase
(MMP)-1, -2, -7, -9, -11, -13 and –14, tissular inhibitors of metalloproteinase (TIMP)-1, -2 and -3. More than 2600 determinations on
cancer specimens from 131 patients with primary ductal invasive tumours of the breast were performed. To identify specific groups
of tumours with distinct expression profiles the data were analysed by unsupervised hierarchical cluster analysis by each cellular type.
We did not find well-defined cluster of cases for tumour cells or fibroblastic cells. However, for mononuclear inflammatory cells the
dendogram shows a first-order division of the tumours into two distinct MMP/TIMP molecular profiles, designated group 1 (n¼89)
and group 2 (n¼42). Matrix metalloproteinase-7, -9, -11, -13 and -14, and TIMP-1 and -2, were identified as showing significant high
expression in group 2 compared with group 1. Multivariate analysis demonstrated that clustering for mononuclear inflammatory cells
was the most potent independent factor associated with distant relapse-free survival (group 2: 5.6 (3.5–9.6), Po0.001). We identify
a phenotype of mononuclear inflammatory cells infiltrating tumours, which is associated with the development of distant metastasis.
Therefore, this finding suggests that these host inflammatory cells could be a possible target for inhibition of metastasis.
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Degradation of the stromal connective tissue and basement
membrane components are key elements in tumour invasion and
metastasis. Some components of the extracellular matrix, particu-
larly the interstitial collagens, are very resistant to proteolytic
attacks, being degraded only by matrix metalloproteinases (MMPs)
(Nelson et al, 2000). Matrix metalloproteinases are also able to
impact on tumour cell behaviour in vivo as a consequence of their
ability to stimulate the tumoural growth, antiapoptotic factors,
motility cellular or angiogenesis (Manes et al, 1999; Rifkin et al,
1999; Fingleton et al, 2001; Noe et al, 2001; Sternlicht and Werb,
2001; Egeblad and Werb, 2002; Turk et al, 2004).
Several MMPs, in particular the gelatinases MMP-2 (Jones et al,
1999; Duffy et al, 2000; Talvensaari-Mattila et al, 2001, 2003; Baker
et al, 2002; Grieu et al, 2004; Li et al, 2004; Sivula et al, 2005) and
MMP-9 (Chantrain et al, 2004; Li et al, 2004; Pellikainen et al,
2004), have been recently studied as prognostic factors in breast
cancer, being associated with a poor outcome in various subsets of
patients. Discordant data have also been published on the
prognostic value of the above-mentioned MMPs (Jones et al,
1999; Hirvonen et al, 2003; Talvensaari-Mattila et al, 2003; Grieu
et al,2 0 0 4 ;S i v u l aet al, 2005; Talvensaari-Mattila and Turpeenniemi-
Hujanen, 2005). Nevertheless, it has been suggested that the
coexpression of various MMPs and/or tissular inhibitors of
metalloproteinases (TIMPs) might provide additional prognostic
information in breast cancer. Accordingly, it has been reported
that several other MMPs and TIMPs may be overexpressed and/or
related to clinical outcome in breast cancer, such as MMP-11
(Duffy et al, 2000) MT1-MMP (MMP-14) (Jones et al, 1999; Mimori
et al, 2001) MMP-13 (Nielsen et al, 2001), TIMP-1 (Ree et al, 1997;
McCarthy et al, 1999; Nakopoulou et al, 2002a; Schrohl et al, 2003,
2004) or TIMP-2 (Visscher et al, 1994; Ree et al, 1997; Remacle
et al, 2000). In addition, there are at least two elements adding
more complexity to the role of MMPs and TIMPs in cancer. On the
one hand, it is now assumed that TIMPs are multifactorial proteins
also involved in the induction of proliferation and the inhibition
of apoptosis (Baker et al, 1999; Jiang et al, 2002) TIMP-3 (Guedez
et al, 2001) and TIMP-1. On the other hand, we should consider
that the cellular type (tumoural cell/stromal cell) expressing these
factors might be of biological importance in breast cancer (see
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sDecock et al, 2005, for review). Thus, for example, it has been
demonstrated that positive stromal MMP-9 expression is related to
HER-2 overexpression in oestrogen receptor-positive tumours and
predicts a shorter relapse-free and overall survival, whereas MMP-9
expression in carcinomatous cells predicts a longer relapse-free
survival (Pellikainen et al, 2004).
All these data suggest the importance of the consideration of
new techniques that would allow evaluation of the expression of
several MMPs and TIMPs by each cellular type of the tumoural
scenario, to contribute to the understanding of the molecular
complexity of breast cancer and to a more precise prognostic
evaluation. Immunohistochemistry on tissue microarrays (TMAs)
provide an efficient platform to observe protein expression in a
large number of cases with a limited amount of reagents and with a
short analysis time (Gulmann et al, 2003). Recently, we reported
the clinical value of this technology to evaluate the expression of
MMP-1, -2, -7, -9, -11, -13 and –14, and TIMP-1, -2 and 3, in breast
cancer (Vizoso et al, 2007). In this study, we validated this method
against the determination of the expression of these parameters in
the whole-tissue sections of the tumours, and we also found
significant associations between the expression of several MMPs
and the occurrence of distant metastasis. Following with our
investigations, the objectives of the present work were (i) to
investigate the relationship between these several MMPs and
TIMPs expressions by the cellular type (tumoural/stromal cells)
and the clinicopathological and biological characteristics of the
tumours; and (ii) to attempt the identification of the different
phenotypes of tumour or stromal cells associated with the
development of distant metastases.
MATERIALS AND METHODS
Patients’ selection
This study comprised 131 women with a histologically confirmed
diagnosis of early invasive breast cancer of ductal-type treated
between 1990 and 2001, which were previously included in our
preliminary study on the expression of MMPs and TIMPs in breast
cancer (Vizoso et al, 2007). This study population include a
significant number of patients with relapse in both node-negative
and node-positive patient’s subgroups (half of cases with distant
metastasis during the follow-up period in each one of these
subgroups) for securing the statistical power of the survival
analysis. Data about treatment and following of the patients were
described elsewhere (Vizoso et al, 2007). The study adhered to
national regulations and was approved by our Institution’s Ethics
and Investigation Committee.
Tissue microarrays and immunohistochemistry
Routinely fixed (overnight in 10% buffered formalin), paraffin-
embedded tumour samples stored in our pathology laboratory files
were used in this study. Details about TMAs technique were
described elsewhere (Vizoso et al, 2007). From the 131 tumour
samples available, four tissue array blocks were prepared, each
containing 33 tumour samples, as well as internal controls
including four normal breast tissue samples from two healthy
women that underwent reductive mammary surgery. Immuno-
histochemistry was carried out on sections of 5mm of TMA fixed
in 10% buffered formalin and embedded in paraffin using a
TechMate TM50 autostainer (Dako, Glostrup, Denmark). Anti-
bodies for MMPs and TIMPs were obtained from Neomarker (Lab
Vision Corporation, Fremont, CA, USA). The dilution for each
antibody was established based on negative and positive controls
(1 out of 50 for MMP-2, -7 and -14, TIMP-2 and -3; 1 out of 100 for
MMP-1, -9 and -13 and TIMP-1; and 1 out of 200 for MMP-11).
The immunohistochemistry technique was also described for us in
a recent report (Vizoso et al, 2007).
Tissue microarray analysis
For each antibody preparation studied, the location of immuno-
reactivity in each cellular type was determined. In each case,
immunoreactivities were classified into two categories in each cell
type (tumour, fibroblastic and inflammatory mononuclear cells),
depending upon the percentage of cells stained (negative: 0–10%
positive cells; positive: 410% positive cells). We studied both
cores that were carried out for each patient and averaged the
results. If there was no tumour in a particular core, then the results
of the other was given. Staining was studied by two pathologists
(LOG and AMM) blinded to the clinical outcome of the patients.
Western blot analysis
Western blotting of metalloproteinases (MMP-1, -11, -13 and -14)
from human breast cancer cytosolic extracts or from human
placenta (used as positive control) was performed as follows:
samples were subjected to 12% SDS–PAGE and transferred onto a
nitrocellulose membrane for 1h at room temperature. Nitrocellu-
lose membrane was blocked with 2% non-fat dry milk in TBS
(50mM Tris–HCl, 100mM NaCl, pH 8.0) with 0.1% Tween 20 for
1h at room temperature. Blots were then immunolabelled over-
night at 41C with a monoclonal anti-MMP-11 (1:200, Lab Vision
Corporation). After three washes for 5min each in TBST,
membranes were incubated with goat anti-mouse IgG (1:2500)
(or 1:5000, anti-rabbit IgG for MMP-1 and -14, see below)
peroxidase-conjugated second antibody, using the ECLt Western
blotting analysis system (Amersham Biosciences, CE Healthcare,
Buckinghamshire, UK), and visualised by placing the blot in
contact with standard X-ray film according to the manufacturer’s
instructions. Membranes were stripped by incubation in 0.2 M
glycine, pH 2.2, containing 0.1% SDS and 1% Tween 20 at room
temperature for 1h, and then re-probed with an anti-MMP-1
(1:200, Lab Vision Corporation), anti-MMP-13 (1:100, Calbio-
chem, Barcelona, Spain), and anti-MMP-14 antiserum (1:200, Lab
Vision Corporation), or an anti-b-actin monoclonal antibody
(1:2500; Sigma-Aldrich, St Louis, MO, USA) to confirm that
equivalent amounts of total protein were added to each well.
Data analysis and statistical methods
Differences in percentages were calculated with the w
2 test. For
metastasis-free survival analysis we used the Cox’s univariate
method. Cox’s regression model was used to examine interactions
of different prognostic factors in a multivariate analysis. Expres-
sion profiles were analysed by unsupervised hierarchical clustering
method that organises proteins in a tree structure, based on their
similarity. Data were reformatted as follows:  3 designated
negative staining, 3 positive staining, missing data were left blank.
The score values were reformatted (positive–negative) choosing
the median as cutoff value. We used the Cluster 3.0 programme
(average linkage, Pearson’s correlation). Results were displayed
with Treeview (Eisen et al, 1998). The SPSS 11.5 programme was
used for all calculations.
RESULTS
Figure 1 shows examples of tissue with immunostaining for
proteins evaluated. The percentage of positive cells for each
protein was always higher than 50% in positive case for each
cellular type.
Matrix metalloproteinase-1 was immunohistochemically de-
tected in 88.3% of breast carcinomas, MMP-2 in 42%, MMP-7 in
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s87.4%, MMP-9 in 74%, MMP-11 in 89.3%, MMP-13 in 73.3%,
MMP-14 in 90%, TIMP-1 in 95%, TIMP-2 in 87% and TIMP-3 in
82.3%. However, there was also variability with regard to the cell
type expressing each protein. For all proteins immunostaining was
localised predominantly in tumour cells, but also in stromal cells
(fibroblasts and/or mononuclear inflammatory cells) in significant
percentages of cases for each studied protein.
To identify specific groups of tumours with distinct MMP/TIMP
immunohistochemical expression profiles the data were analysed
by unsupervised hierarchical cluster analysis by each cellular type.
The algorithm orders proteins on the horizontal axis and samples
on the vertical axis based on similarity of their expression profiles.
This did not produce a dendrogram with well-defined cluster of
cases for tumour cells or fibroblastic cells (Figure 2A and B).
However, for mononuclear inflammatory cells the dendogram
shows a first-order division of the tumours into two distinct MMP/
TIMP molecular profiles, designated group 1 (n¼89) and group 2
(n¼42) (Figure 2C). Matrix metalloproteinase-7, -9, -11, -13 and
-14, and TIMP-1 and -2, were identified as showing significant high
expression in group 2 compared with group 1 (Table 1). The
presence of the proteins was confirmed by Western blot analysis of
breast tumour cytosols samples (Figure 3). Western blots clearly
showed immunoreactive bands corresponding to MMP-1, -11,
-13 and -14 in seven samples from breast carcinomas (Figure 3A,
upper panel). Two major immunoreactive bands were readily
visible in samples from MMP-1 (glycosylated and unglycosylated
form) and MMP-14 (latent and active form). As positive control,
we also performed a Western blot for MMP-11 protein detection
in placenta. As shown in Figure 3B, the anti-MMP-11 antibody
recognised a band of approximately 47kDa corresponding to the
expected size in both, breast carcinomas (lanes 1 and 2), and
placenta (lane 3).
These two groups showed significant differences with regard to
PgR status and peritumoural inflammation. Group 1 showed a
higher percentage of PgR-positive tumours, whereas group 2
showed a higher percentage of tumours with peritumoural
inflammation. In addition, group 2 showed a significantly higher
percentage of tumours positive for TIMP-1, MMP-9 and -11 in the
tumour cells; as well as a significantly higher percentage of
tumours positive for TIMP-2, TIMP-3, MMP-9, -11, -13 and -14,
in fibroblastic cells (Table 2). However, our result did not show
significant association between the cluster group of tumours with
other clinicopathological characteristics, such as age, menopausal
stage, tumour size, nodal status, histological grade, Nottingham
Prognostic Index, oestrogen receptors, desmoplastic reaction,
tumour advancing edge or vascular invasion (data not shown).
On the other hand, during the study period, distant metastasis-
relapse was confirmed in 41 of 42 (97.61%) patients of group 2
tumours and only in 24 of 89 (26.96%) patients of group 1
tumours. Kaplan–Meier analysis shows that the difference in
relapse-free survival between these two groups is highly and
statistically significant (Po0.0001; Figure 4). Multivariate analysis
according to Cox model demonstrated that tumoural stage (II:
(relative risk (RR) (confidence interval (CI)¼1.6 (0.8–3.1); III: 3.5
(1.7–7.1); Po0.001) and ER status (positive: 0.5 (0.3–0.8),
Po0.001) were significantly and independently associated with
relapse-free survival. However, this same analysis also demon-
strated that clustering for mononuclear inflammatory cells was the
most potent independent factor associated with relapse-free
survival (group 2: 5.6 (3.5–9.6), Po0.001).
DISCUSSION
The results of the present study led us to several considerations, on
the cellular type expressing each MMPs or TIMPs, the cellular
origin of its production, the importance of stromal–tumour cell
interactions, and the clinical value of these proteins not only in
predicting outcome in breast cancer but also as a potential
biological therapeutic target.
Breast cancer, as a solid tumour, consists of a variable mixture
of neoplastic cells and non-neoplastic tumour stroma, comprising
endothelial cells, pericytes, fibroblast cells and variable representa-
tion of inflammatory cells. Over the past few years, evidence shows
Cluster 2
Cluster 1
ABC
F E D
Figure 1 Left: examples of tissue with immunostaining for the more significant proteins in patients with tumours belong to poor prognostic group (cluster
2 group: A, B and C) and better prognostic group (cluster 1 group: D, E and F; magnification  400). (A) Immunohistochemical staining of matrix
metalloproteinase (MMP)-11 in inflammatory mononuclear cells, tumour cells and fibroblastic cells. (B) Immunohistochemical staining of MMP-9 in
inflammatory mononuclear cells, tumour cells and fibroblastic cell negatives. (C) Immunohistochemical staining of tissular inhibitors of metalloproteinase
(TIMP)-1 in inflammatory mononuclear cells and in fibroblastic cells, tumour cell negatives. (D) No immunohistochemical staining of MMP-9 in inflammatory
mononuclear cells, tumour cells and fibroblastic cells. (E) Immunohistochemical staining of MMP-11 in tumour cells, inflammatory mononuclear cells and
fibroblastic cell negatives. (F) Immunohistochemical staining of TIMP-1 in fibroblastic cells, inflammatory mononuclear cells and tumour cell negatives. In all
cases, inflammatory mononuclear cells are indicated with small arrows, and fibroblastic cells with large arrows.
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sthat both changes in stromal behaviour and the interaction
between tumour cells and stromal cells are intimately linked to the
processes of tumorigenesis, tumour invasion and metastasis
(Liotta and Kohn, 2001; Bhowmick et al, 2004). Infact, it is now
known that in addition to their production by epithelial tumour
cells, MMP and/or TIMP gene expression may be induced in
stromal fibroblasts and/or in vascular and inflammatory cells that
infiltrate tumours around them (Visscher et al, 1994; Nielsen et al,
2001; Nakopoulou et al, 2002b; De Wever and Mareel, 2003).
Table 1 Expression of MMPs and TIMPs in two cluster groups of breast
carcinomas with distinct MMP/TIMP molecular profile in the stromal
mononuclear inflammatory cells
Group 1 n¼89 Group 2 n¼42 P-value
MMP-1 53 (61.6) 32 (76.2) NS
MMP-2 1 (1.1) 1 (2.4) NS
MMP-7 33 (38.8) 30 (71.4) 0.001
MMP-9 0 14 (33.3) 0.0001
MMP-11 4 (4.6) 36 (85.7) 0.0001
MMP-13 21 (23.6) 23 (54.8) 0.001
MMP-14 29 (32.6) 38 (90.5) 0.0001
TIMP-1 9 (10.1 24 (57.1) 0.0001
TIMP-2 15 (16.9) 35 (83.3) 0.0001
TIMP-3 43 (48.3) 26 (61.9) NS
Data are expressed as number of cases (%). Note: samples on tissue sections were
either insufficient or lost for analysis in three cases for MMP1, two cases for MMP-2,
four cases for MMP-7, one case for MMP-9, two cases for MMP-11, one case for
TIMP-1 and one case for TIMP-2. The values shown corresponding to the total
number of cases were analysed for each protein.
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Figure 2 Hierarchical clustering analysis of global matrix metalloproteinases (MMPs)/tissular inhibitors of metalloproteinases (TIMPs) expressions in the
different cell types of breast cancer as measured by immunohistochemistry on tissue microarray (TMA). Graphical representation of hierarchical clustering
results in tumour cells (A), fibroblasts (B) and mononuclear inflammatory cells (C). Rows, tumoural samples; columns, MMPs/TIMPs. Protein expressions are
depicted according to a color scale: red, positive staining; green, negative staining; grey, missing data. No major clusters of tumours are shown in tumour cells
and fibroblasts. Two major clusters of tumours (1 and 2) are shown in mononuclear inflammatory cells.
(Glycosylated) 47 kDa
(Unglycosylated) 42 kDa
50 kDa
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(Latent form) 66 kDa
(Active form) 54 kDa
12 3
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456 78
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-Actin
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MMP-1
Figure 3 (A) Representative Western blots of immunoreactive matrix
metalloproteinases (MMPs). (A) Eighty micrograms of cytosol extract from
seven human breast carcinomas (lanes 2–8) were subject to 12% SDS–
PAGE and transferred onto a nitrocellulose membrane and then
immunolabelled with MMP-1, -11, -13, -14 and b-actin (used as loading
control) antiserum. Lane 1, molecular weight marker (50kDa). (B)
Western blots of immunoreactive MMP-11 and b-actin (used as loading
control) from two human breast carcinomas (lanes 1 and 2) and from
human placenta (used as positive control, lane 3).
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sLikewise, a number of reports have indicated that the main source
of MMPs in breast carcinoma is the stromal cell (Soini et al, 1994;
Heppner et al, 1996; Brummer et al, 1999; Nakopoulou et al, 1999),
and experimental studies have also demonstrated a mechanism
by which breast cancer cells can rapidly use MMPs produced by
adjacent normal fibroblasts to facilitate their invasion of the
peritumoural tissue (Saad et al, 2002). In any case, in the present
study it especially relevant to the finding of a positive and
significant relationship between the expression of components of
the matrix-degrading protease system by stromal cells of the
tumours, such as fibroblasts or inflammatory cells, and several
parameters indicators of tumoural aggressiveness, such as large
size, lymph node involvement, high Nottingham Prognostic Index,
infiltrating edge, desmoplastic reaction or peritumoural inflam-
mation. In addition, we identify a subset of breast tumours having
a phenotype of inflammatory mononuclear cells expressing MMPs
and TIMPs, which was notably associated with a high relapse rate
of distant metastasis. Therefore, this suggests that the tumoural
stroma does not merely play a passive role in cancer progression.
Rather, it may in fact actively participate in the process of cancer
invasion.
Inflammatory cells can account for as much as 50% of the total
tumour mass in invasive breast carcinomas. Mononuclear
inflammatory cells infiltrate in breast carcinomas include a
variable representation of macrophages, plasma cells, mast cells
and B and T lymphocytes (Coussens and Werb, 2002; Lin and
Pollard, 2004). Historically, tumour-infiltrating leukocytes have
been considered to be manifestations of an intrinsic defence
mechanism against developing tumours (Johnson et al, 1989; Lin
and Pollard, 2004). However, our data are in accordance with the
increasing evidence indicating that leukocytes infiltration can
promote tumour phenotypes, such as angiogenesis, growth and
invasion (Adams et al, 1987; Coussens and Werb, 2002; Daniel
et al, 2005). This may be due to inflammatory cells probably
influencing cancer promotion by secreting cytokines, growth
factors, chemokines and proteases, which stimulate proliferation
invasiveness of cancer cells. Nevertheless, the prognostic signifi-
cance of the lymphoid infiltrate at the tumour site remains
controversial, perhaps because the evaluation criteria for tumour
infiltrates are not sufficiently standardised to yield reliable and
reproducible results in different institutions. Therefore, our results
may contribute to characterise a phenotype of infiltrating mono-
nuclear inflammatory cells associated with a poorer prognosis
in breast cancer. These mononuclear inflammatory cells
were characterised by the expression of MMP-7, -9, -11, -13, -14,
TIMP-1 and -2.
Matrix metalloproteinase-7 (matrilysin 1) is a stromelysin,
which degrades type IV collagen, fibronectin and laminin. It was
showed that MMP-7 is aberrantly expressed in human breast
tumours, and that elimination of MMP-7 is associated with low
invasiveness and slow tumour growth (Jiang et al, 2005). Matrix
metalloproteinase-9 (gelatinase B) is related to tumour invasion
and metastasis by their special capacity to degrade the type IV
collagen found in basement membranes (Jones and Walker, 1997),
and to induce angiogenesis (Egeblad and Werb, 2002). High MMP-
9 expression correlates significantly with tumoural aggressiveness
and poor prognosis (Chantrain et al, 2004; Li et al, 2004;
Pellikainen et al, 2004). Similarly to other studies, our data
showed that MMP-11 (Stromalysin-3) was preferentially expressed
by peritumoural stromal cells (Basset et al, 1990, 1997) and that
high levels of MMP-11 were associated with tumour progression
and poor prognosis (Muller et al, 1993; Anderson et al, 1995;
Chenard et al, 1996; Ahmad et al, 1998; Tetu et al, 1998; Lochter
Table 2 Number and percentage of positive cases of tumours for the
different MMPs and TIMPs expressions, in tumour cells or fibroblastic cells,
in the different cluster groups
Group 1 n¼89 Group 2 n¼42 P-value
MMP-7
TC 72 (84.7) 32 (92.9) NS
FC 57 (67.1) 33 (78.6) NS
MIC 33 (38.8) 30 (71.4) 0.001
MMP-9
TC 57 (64.8) 38 (90.5) 0.004
FC 6 (6.8) 14 (33.3) o0.001
MIC 0 14 (33.3) o0.001
MMP-11
TC 73 (83.9) 41 (97.6) 0.04
FC 48 (55.2) 40 (95.2) o0.001
MIC 4 (4.6) 36 (85.7) o0.001
MMP-13
TC 65 (73) 32 (76.2) NS
FC 36 (40.4) 28 (66.7) 0.009
MIC 21 (23.6) 23 (54.8) 0.001
MMP-14
TC 77 (86.5) 41 (97.6) NS
FC 67 (75.3) 39 (92.9) 0.03
MIC 29 (32.6) 38 (90.5) o0.001
TIMP-1
TC 82 (92.1) 41 (97.6) NS
FC 41 (46.1) 23 (54.8) NS
MIC 9 (10.1) 24 (57.1) o0.001
TIMP-2
TC 69 (77.5) 41 (97.6) 0.008
FC 21 (23.6) 34 (81) o0.001
MIC 15 (16.9) 35 (83.3) o0.001
TIMP-3
TC 75 (84.3) 38 (90.5) NS
FC 46 (51.7) 34 (81) 0.003
MIC 43 (48.3) 26 (61.9) NS
F¼fibroblasts; MIC¼mononuclear inflammatory cells; MMP¼matrix metallopro-
teinase; TC¼tumoural cells; TIMP¼tissular inhibitors of metalloproteinase. Data are
expressed as number of cases (%). Note: samples on tissue sections were either
insufficient or lost for analysis in four cases for MMP-7, one case for MMP-9, two
cases for MMP-11, one case for TIMP-1 and one case for TIMP-2. The values shown
corresponding to the total number of cases were analysed for each protein.
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Figure 4 Kaplan–Meier survival curves as a function of the two major
clusters of tumours (Groups 1 and 2) shown in mononuclear inflammatory
cells.
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set al, 1999; Nakopoulou et al, 2002b). Matrix metalloproteinase-13
(collagenase-3) has been found to have an exceptionally wide
substrate specificity when compared with other MMPs (Freije et al,
1994; Knauper et al, 1997). Moreover, it is thought to play a central
role in the MMP activation cascade, both activating and being
activated by several other MMPs (MMP-14, -2 or -3). Nielsen et al
(2001) have reported that MMP-13 expression by myofibroblasts
was often associated with microinvasive events, and they have
proposed that this MMP may play an essential role during the
transition of ductal carcinoma in situ lesions to invasive ductal
carcinoma of the breast. Matrix metalloproteinase-14 (membrane
type 1 MMP or MT1-MMP) is a key metalloprotease involved in
the degradation of extracellular matrix, activates pro-MMP-13
(Knauper et al, 1996) and pro-MMP-2 (Strongin et al, 1995) on the
cell surface, and plays crucial roles in molecular carcinogenesis,
tumour cell growth, invasion and angiogenesis. On the other hand,
the positive relationship between TIMP expression by inflamma-
tory mononuclear cells and cancer progression could look
paradoxical, because both TIMP-1 and -2 are well-known
inhibitors of MMP activity. If TIMPs inhibit MMPs in vivo,i t
should be expected that high levels of inhibitors would prevent
tumour progression and thus relate to good outcome in patients
with cancer. However, there is an increasing body of evidence
suggesting that TIMPs are multifunctional proteins that, in
addition to its MMP-inhibitory effect, also promote the prolifera-
tion of some cell types, and their antiapoptotic effects may favour
tumour expansion during the onset and early growth of the
primary tumour (Guedez et al, 1998, 2001; Baker et al, 1999; Jiang
et al, 2002).
The unresolved question is, if the mononuclear inflammatory
cells merely respond to signals from the carcinoma cells or
respond in self-addressed envelope on tumour progression. Even
so, in the present study, we identify a phenotype of mononuclear
inflammatory cells infiltrating tumours, characterised by the
expression of a specific panel of MMPs and TIMPs, which is
associated with the development of distant metastasis. Therefore,
this finding is of great clinical interest and it also suggests that
these host inflammatory cells could be a possible target for
inhibition of tumour progression and metastasis.
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